SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Zhongping Lily Mao, Nishit B. Modi, Dose-Response Analysis of the Effect of Carbidopa-Levodopa Extended-Release Capsules (IPX066) in Levodopa-Naive Patients With Parkinson Disease, The Journal of Clinical Pharmacology, 2016, 56, 3
  2. 2
    Nalin Payakachat, Mir M. Ali, J. Mick Tilford, Can The EQ-5D Detect Meaningful Change? A Systematic Review, PharmacoEconomics, 2015, 33, 11, 1137

    CrossRef

  3. 3
    Ingrid H.W.M. Sturkenboom, Jan C.M. Hendriks, Maud J.L. Graff, Eddy M.M. Adang, Marten Munneke, Maria W.G. Nijhuis-van der Sanden, Bastiaan R. Bloem, Economic evaluation of occupational therapy in Parkinson's disease: A randomized controlled trial, Movement Disorders, 2015, 30, 8
  4. 4
    Anette Schrag, Anna Sauerbier, Kallol Ray Chaudhuri, New clinical trials for nonmotor manifestations of Parkinson's disease, Movement Disorders, 2015, 30, 11
  5. 5
    Richard Dodel, Bengt Jönsson, Jens Peter Reese, Yaroslav Winter, Pablo Martinez-Martin, Robert Holloway, Cristina Sampaio, Evžen Růžička, Graeme Hawthorne, Wolfgang Oertel, Werner Poewe, Glenn Stebbins, Oliver Rascol, Christopher G. Goetz, Anette Schrag, Measurement of costs and scales for outcome evaluation in health economic studies of Parkinson's disease, Movement Disorders, 2014, 29, 2
  6. 6
    Tasos Karakostas, Simon Hsiang, Heather Boger, Lawrence Middaugh, Ann-Charlotte Granholm, Three-dimensional rodent motion analysis and neurodegenerative disorders, Journal of Neuroscience Methods, 2014, 231, 31

    CrossRef

  7. 7
    Marjolein A. Marck, Bastiaan R. Bloem, George F. Borm, Sebastiaan Overeem, Marten Munneke, Mark Guttman, Effectiveness of multidisciplinary care for Parkinson's disease: A randomized, controlled trial, Movement Disorders, 2013, 28, 5
  8. 8
    Marina Picillo, Roberto Erro, Gabriella Santangelo, Rosario Pivonello, Katia Longo, Claudia Pivonello, Carmine Vitale, Marianna Amboni, Marcello Moccia, Annamaria Colao, Paolo Barone, Maria Teresa Pellecchia, Insulin-like growth factor-1 and progression of motor symptoms in early, drug-naïve Parkinson’s disease, Journal of Neurology, 2013, 260, 7, 1724

    CrossRef

  9. 9
    Tanya Simuni, Sheng T. Luo, Kelvin L. Chou, Hubert Fernandez, Bo He, Sotirios Parashos, Rankin scale as a potential measure of global disability in early Parkinson’s disease, Journal of Clinical Neuroscience, 2013, 20, 9, 1200

    CrossRef

  10. 10
    Anthony E. Lang, Eldad Melamed, Werner Poewe, Olivier Rascol, Trial designs used to study neuroprotective therapy in Parkinson's disease, Movement Disorders, 2013, 28, 1
  11. 11
    Stephanie Lessig, Dong Nie, Ronghui Xu, Jody Corey-Bloom, Changes on brief cognitive instruments over time in Parkinson's disease, Movement Disorders, 2012, 27, 9
  12. 12
    Jörg B. Schulz, Effects of selegiline and rasagiline on disease progression in Parkinson’s disease, Basal Ganglia, 2012, 2, 4, S41

    CrossRef

  13. 13
    Sabrina Schröder, Peter Martus, Per Odin, Marion Schaefer, Impact of community pharmaceutical care on patient health and quality of drug treatment in Parkinson’s disease, International Journal of Clinical Pharmacy, 2012, 34, 5, 746

    CrossRef

  14. 14
    Martina Mancini, Patricia Carlson-Kuhta, Cris Zampieri, John G. Nutt, Lorenzo Chiari, Fay B. Horak, Postural sway as a marker of progression in Parkinson's disease: A pilot longitudinal study, Gait & Posture, 2012, 36, 3, 471

    CrossRef

  15. 15
    Katrina L. Paumier, Andrew D. Siderowf, Peggy Auinger, David Oakes, Lalitha Madhavan, Alberto J. Espay, Fredy J. Revilla, Timothy J. Collier, Tricyclic antidepressants delay the need for dopaminergic therapy in early Parkinson's disease, Movement Disorders, 2012, 27, 7
  16. 16
    Olivier Rascol, Cheryl J Fitzer-Attas, Robert Hauser, Joseph Jankovic, Anthony Lang, J William Langston, Eldad Melamed, Werner Poewe, Fabrizio Stocchi, Eduardo Tolosa, Eli Eyal, Yoni M Weiss, C Warren Olanow, A double-blind, delayed-start trial of rasagiline in Parkinson's disease (the ADAGIO study): prespecified and post-hoc analyses of the need for additional therapies, changes in UPDRS scores, and non-motor outcomes, The Lancet Neurology, 2011, 10, 5, 415

    CrossRef

  17. 17
    Jonathan R Evans, Roger A Barker, Defining meaningful outcome measures in trials of disease-modifying therapies in Parkinson's disease, Expert Opinion on Pharmacotherapy, 2011, 12, 8, 1249

    CrossRef

  18. 18
    Pablo Martinez-Martin, Martine Jeukens-Visser, Kelly E. Lyons, C. Rodriguez-Blazquez, Caroline Selai, Andrew Siderowf, Mickie Welsh, Werner Poewe, Oliver Rascol, Cristina Sampaio, Glenn T. Stebbins, Christopher G. Goetz, Anette Schrag, Health-related quality-of-life scales in Parkinson's disease: Critique and recommendations, Movement Disorders, 2011, 26, 13
  19. 19
    Eva-Maria Hametner, Klaus Seppi, Werner Poewe, Pramipexole extended release in Parkinson’s disease, Expert Review of Neurotherapeutics, 2011, 11, 9, 1229

    CrossRef

  20. 20
    Jens Klotsche, Jens Peter Reese, Yaroslav Winter, Wolfgang H. Oertel, Hyacinth Irving, Hans-Ulrich Wittchen, Juergen Rehm, Richard Dodel, Trajectory Classes of Decline in Health-Related Quality of Life in Parkinson's Disease: A Pilot Study, Value in Health, 2011, 14, 2, 329

    CrossRef

  21. 21
    Melinda Hermanns, Weathering the Storm, Journal of Christian Nursing, 2011, 28, 2, 76

    CrossRef

  22. 22
    Ying Jiao Zhao, Hwee Lin Wee, Yiong-Huak Chan, Soo Hoon Seah, Wing Lok Au, Puay Ngoh Lau, Emmanuel Camara Pica, Shu Chuen Li, Nan Luo, Louis C.S. Tan, Progression of Parkinson's disease as evaluated by Hoehn and Yahr stage transition times, Movement Disorders, 2010, 25, 6
  23. 23
    Nan Luo, Wai-Yee Ng, Puay-Ngoh Lau, Wing-Lok Au, Louis CS Tan, Responsiveness of the EQ-5D and 8-item Parkinson’s Disease Questionnaire (PDQ-8) in a 4-year follow-up study, Quality of Life Research, 2010, 19, 4, 565

    CrossRef